Northern TK Venture Pte Ltd. (NTK), an indirect subsidiary of IHH Healthcare Berhad, has raised its damages claim against Daiichi Sankyo Company, Limited from $179.7m (¥20b / RM 634m) to $1.8b ...

Chief Medical Officer of Ascentage Pharma, commented: “We are pleased that results from the ongoing Phase 1b/2 study of lisaftoclax will be featured in an oral presentation at the 2025 ASCO ...

“This year’s ASCO marks the fourth in a row where potential practice-changing ENHERTU data will be showcased,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “With the results of ...

"This year's ASCO marks the fourth in a row where potential practice-changing ENHERTU data will be showcased," said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. "With the results of ...

The data we and our research colleagues are presenting at ASCO demonstrate the clear and growing contribution of liquid biopsy in transforming cancer care and helping to improve patient outcomes.